^
5d
A prospective, single-center, single-arm study of mitoxantrone hydrochloride liposome injection combined with venetoclax and azacitidine in the treatment of newly diagnosed and relapsed/refractory acute myeloid leukemia (ChiCTR2400091259)
P4, N=40, Not yet recruiting, General Hospital of Chinese People's Liberation Army Northern Theater Command; General Hospital of Chinese People's Liberation Army Northern Theater C
New P4 trial
|
Venclexta (venetoclax) • azacitidine • Duoenda (mitoxantrone liposomal)
7d
SPAG6 overexpression decreases the pro-apoptotic effect of daunorubicin in acute myeloid leukemia cells through the ROS/JNK MAPK axis in a GSTP1-dependent manner. (PubMed, Front Pharmacol)
Simultaneously, the elevation of GSTP1 and JNK complex may reduce the expression of p-JNK and inhibit the activation of JNK pathway, which might inhibit cell apoptosis. In conclusion, our experiments suggested that upregulated SPAG6 might mitigate the pro-apoptotic effects of DNR through ROS/JNK MAPK axis in a GSTP1-dependent manner.
Journal
|
GSTP1 (Glutathione S-transferase pi 1)
|
daunorubicin
21d
Single-cell transcriptomics reveals tumor microenvironment changes and prognostic gene signatures in hepatocellular carcinoma. (PubMed, Int Immunopharmacol)
Cell communication analysis among tumor-infiltrating immune cells reveals significant differences in the main signaling pathways at different stages of HCC progression. Finally, drug sensitivity analysis based on key genes identifies Acetalax, Allopurinol, and Amonafide as potential candidates for HCC treatment.
Journal • Gene Signature
|
YY1 (YY1 Transcription Factor)
|
Quinamed (amonafide)
22d
Modelling post-chemotherapy stem cell dynamics in the bone marrow niche of AML patients. (PubMed, Sci Rep)
The "7+3 regimen", which consists of 7 days of cytarabine in combination with daunorubicin during the first 3 days, is a widely used therapy protocol. These simulations are in line with the clinical finding that G-CSF priming can improve the treatment outcome. Furthermore, our model suggests that a decline of HSC counts during remission might serve as an indication for salvage therapy in patients lacking MRD (minimal residual disease) markers.
Journal • IO biomarker
|
CD38 (CD38 Molecule) • CD34 (CD34 molecule)
|
cytarabine • daunorubicin
24d
MiR-133 promotes the multidrug resistance of acute myeloid leukemia cells (HL-60/ADR) to daunorubicin. (PubMed, Cytotechnology)
Mechanistically, the NF-κB signaling pathway regulates the expression of miR-133 in HL-60/ADR cells, and the targeting of CXCL12 by miR-133 enhances the resistance of HL-60/ADR cells to DNR. In conclusion, the NF-κB signaling pathway regulates the expression of miR-133, and inhibiting miR-133 expression can target CXCL12 to increase the sensitivity of HL-60/ADR cells to DNR.
Journal
|
CXCL12 (C-X-C Motif Chemokine Ligand 12)
|
daunorubicin
24d
New P1 trial
|
cytarabine • doxorubicin hydrochloride • decitabine • Duoenda (mitoxantrone liposomal)
28d
Branched oncolytic peptides target HSPGs, inhibit metastasis, and trigger the release of molecular determinants of immunogenic cell death in pancreatic cancer. (PubMed, Front Mol Biosci)
Remarkably, the cytotoxicity induced by BOPs triggers the release of DAMPs, particularly HMGB1, IFN-β and ATP, by dying cells, persisting longer than the cytotoxicity of conventional chemotherapeutic agents such as irinotecan and daunorubicin. An in vivo assay in nude mice showed an encouraging 20% inhibition of tumor grafting and growth in a pancreatic cancer model by BOP9.
Journal
|
HMGB1 (High Mobility Group Box 1) • IFNB1 (Interferon Beta 1)
|
irinotecan • daunorubicin
1m
The DHODH inhibitor teriflunomide impedes cell proliferation and enhances chemosensitivity to daunorubicin (DNR) in T-cell acute lymphoblastic leukemia. (PubMed, Ann Hematol)
Moreover, combined treatment with TRF and daunorubicin (DNR) significantly reduced cell viability and promoted apoptosis in DNR-resistant T-ALL cells. Our study provides valuable insights into the critical role of TRF in treating T-ALL while increasing the sensitivity of DNR-resistant T-ALL cells to DNR.
Journal
|
TP53 (Tumor protein P53) • BTG2 (BTG Anti-Proliferation Factor 2)
|
TP53 expression
|
daunorubicin
1m
New P2 trial
|
Venclexta (venetoclax) • Duoenda (mitoxantrone liposomal)
1m
New trial
|
Venclexta (venetoclax) • Duoenda (mitoxantrone liposomal)
2ms
Influence of Redox-Active Chitosan-Polyaminoxyl Micelles Loaded with Daunorubicin on Activity of Nrf2 Transcription Factor. (PubMed, Bull Exp Biol Med)
Increased nuclear translocation of Nrf2 leads to a significant increase in the expression of its target gene TXN1, but not the NQO1, GPX1, and HMOX1 genes, the increased expression of which can lead to the development of resistance to anthracycline antibiotics. Redox-active CPA micelles have great potential for the development of nanoparticles for the transport of anthracycline antibiotics in experimental tumor chemotherapy, and also as promising activators of Nrf2 transcription factor.
Journal
|
HMOX1 (Heme Oxygenase 1) • NQO1 (NAD(P)H dehydrogenase, quinone 1)
|
HMOX1 expression
|
daunorubicin
2ms
A multifunctional DNA tetrahedron for imaging, gene therapy, and chemotherapy-phototherapy combination: Binding affinity and anticancer activity. (PubMed, Int J Biol Macromol)
In this study, we designed a multifunctional DNA tetrahedron (MB-MUC1-TD) for the targeted delivery of combined daunorubicin (DAU) + toluidine blue O (TBO)...In vitro cytotoxicity showed better gene therapy efficacy of MB on MCF-7 cells, better biocompatibility of loaded DAU and TBO on LO2 cells, and stronger synergistic cytotoxicity of DAU + TBO on MCF-7/ADR cells. This study may establish a theoretical foundation for co-loading CTPT combination drugs based on multifunctional DNA nanostructures.
Journal • Gene therapy • Epigenetic controller
|
MUC1 (Mucin 1) • MIR21 (MicroRNA 21)
|
daunorubicin
2ms
Design and synthesis of novel multi-target tetrabromophthalimides as CBS and Topo-II inhibitors and DNA intercalators. (PubMed, RSC Med Chem)
Hence, this work was tailored to design and synthesize new multi-target tetrabromophthalimide derivatives (2a-2k) that are capable of inhibiting the colchicine binding site (CBS) and topoisomerase II (Topo-II)...Furthermore, the Topo-II inhibition assay displayed the prominent inhibitory potential of compound 2f with an IC50 value of 15.75 μg mL-1, surpassing the IC50 of etoposide (20.82 μg mL-1)...The new candidates were docked against both the CBS (PDB ID: 5XIW) and Topo-II (PDB ID: 5CDP) targets to investigate their binding interactions and affinities as well. Accordingly, the synthesized compounds could serve as promising multi-target anticancer candidates with eligible apoptotic activity.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • MMP2 (Matrix metallopeptidase 2) • BAX (BCL2-associated X protein) • MMP9 (Matrix metallopeptidase 9)
|
etoposide IV
2ms
New P4 trial • Real-world evidence • Real-world
|
bortezomib • carfilzomib • dexamethasone • pomalidomide • Duoenda (mitoxantrone liposomal)
2ms
Mitoxantrone Hydrochloride Liposome Combined With Capecitabine in Patients With HER-2 Negative Advanced Breast Cancer (ChiCTR2400088245)
P1, N=48, Recruiting, Cancer Hospital Chinese Academy of Medical Sciences; Cancer Hospital Chinese Academy of Medical Sciences
New P1 trial • Metastases
|
HER-2 (Human epidermal growth factor receptor 2)
|
HR positive • HER-2 negative
|
capecitabine • Duoenda (mitoxantrone liposomal)
2ms
Adipocyte maturation impacts daunorubicin disposition and metabolism. (PubMed, Eur J Clin Invest)
Fat is an expandable tissue that can sequester and detoxify DNR when stimulated by obesity, likely through the upregulation of DNR-metabolizing enzymes AKR1C3 and CBR1. Our data partially explains why obese ALL patients may be more likely to become chemoresistant towards DNR, and provides evidence for potential clinical investigation targeting obesity to reduce DNR chemoresistance.
Journal
|
AKR1C3 (Aldo-Keto Reductase Family 1 Member C3)
|
daunorubicin
3ms
Hypoxia-initiated Cysteine-rich protein 61 secretion promotes chemoresistance of acute B lymphoblastic leukemia cells. (PubMed, Am J Cancer Res)
Increased Cyr61 expression appears to reduce the chemosensitivity of B-ALL cell to vincristine (VCR) and daunorubicin (DNR) through autophagy under hypoxia. Notably, inhibition of Cyr61 restores the chemosensitivity of B-ALL cells to both chemotherapeutic agents. This study is the first time to report that hypoxia decreases the chemosensitivity of B-ALL cells by inducing Cyr61 production, suggesting that targeting Cyr61 or its associated pathways could potentially improve the clinical response of B-ALL patients.
Journal
|
CCN1 (Cellular Communication Network Factor 1)
|
vincristine • daunorubicin
4ms
New P1 trial
|
cyclophosphamide • decitabine • Duoenda (mitoxantrone liposomal)
4ms
Phase I Dose Escalation and Pharmacokinetics Clinical Trial of Mitoxantrone Hydrochloride Liposome in Children With Relapsed and Refractory Lymphoma and Solid Tumors (clinicaltrials.gov)
P1, N=68, Active, not recruiting, Sun Yat-sen University | Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2024 --> Sep 2024
Enrollment closed • Trial primary completion date
|
vincristine • Duoenda (mitoxantrone liposomal) • irinotecan liposomal
4ms
CMOP±R in the Treatment of Untreated Non-Hodgkin's Lymphoma (clinicaltrials.gov)
P2, N=197, Not yet recruiting, The First Affiliated Hospital of Soochow University
New P2 trial
|
cyclophosphamide • Duoenda (mitoxantrone liposomal) • vindesine
5ms
MicroRNA‑223 overexpression suppresses protein kinase C ε expression in human leukemia stem cell‑like KG‑1a cells. (PubMed, Mol Clin Oncol)
Two AML cell lines, KG-1 and KG-1a, differing in the proportion of CD34+CD38- cells, were assessed for doxorubicin (DOX) sensitivity using the Cell Counting Kit-8 assay...Daunorubicin was then used to assess drug sensitivity in the siRNA-transfected KG-1a cells...However, despite these effects, miR-223 overexpression and PKCε inhibition did not change drug sensitivity in KG-1a cells compared with negative control cells. In summary, the present study demonstrated that miR-223 could target and silence PKCε expression in KG-1a cells; however, the chemoresistance of KG-1a cells to anthracycline drugs may not be directly associated with the low expression of miR-223.
Journal • IO biomarker
|
CD38 (CD38 Molecule) • CD34 (CD34 molecule) • MIR223 (MicroRNA 223)
|
doxorubicin hydrochloride • daunorubicin
5ms
VMAC+DLI Treatment of Patients With Relapse of AML After Allo-HSCT (clinicaltrials.gov)
P2, N=30, Recruiting, Institute of Hematology & Blood Diseases Hospital, China
New P2 trial
|
Venclexta (venetoclax) • cyclophosphamide • Duoenda (mitoxantrone liposomal)
6ms
New P2 trial
|
Venclexta (venetoclax) • Duoenda (mitoxantrone liposomal)
6ms
CMOEP in the Treatment of Untreated Peripheral T-cell Lymphoma (clinicaltrials.gov)
P2, N=115, Recruiting, Tianjin Medical University Cancer Institute and Hospital
New P2 trial
|
cyclophosphamide • etoposide IV • vincristine • prednisone • Duoenda (mitoxantrone liposomal) • vindesine
6ms
Mechanism of Daunomycin Intercalation into DNA from Enhanced Sampling Simulations. (PubMed, J Phys Chem Lett)
Variability within the ensemble of binding trajectories illuminates differences in the orientation of daunomycin as it initially intercalates; around 10% of trajectories needed minimal rearrangement from intercalation to reaching the fully bound configuration, whereas most needed an additional 1-5 ns to rearrange. The results here emphasize the utility of generating an ensemble of trajectories to discern biomolecular binding mechanisms.
Journal
|
GCG (Glucagon)
6ms
Daunorubicin induces GLI1‑dependent apoptosis in colorectal cancer cell lines. (PubMed, Int J Oncol)
Moreover, a competition experiment using BODIPY‑cyclopamine, a well‑known Smo inhibitor, suggested that daunorubicin does not bind to Smo in HCT116 cells. Taken together, the present results revealed that daunorubicin suppresses canonical Hedgehog pathways in CRC. Ultimately, the present study discloses a new mechanism of daunorubicin's anticancer effect and might provide a rationale for expanding the clinical application of daunorubicin.
Preclinical • Journal
|
TP53 (Tumor protein P53) • GLI1 (GLI Family Zinc Finger 1)
|
daunorubicin • cyclopamine
6ms
Disruption of the hippo pathway promotes the proliferation of childhood acute lymphoblastic leukemia cells, inhibits apoptosis and chemosensitivity. (PubMed, Expert Rev Hematol)
YAP1 knockdown also reduced the IC50 value following treatment with vincristine, daunorubicin, cyclophosphamide, and dexamethasone (p < 0.05). Disruption of the Hippo pathway attenuates the development of cALL by promoting cell proliferation, while suppressing apoptosis and drug sensitivity.
Journal
|
YAP1 (Yes associated protein 1) • CCN1 (Cellular Communication Network Factor 1)
|
YAP1 overexpression
|
cyclophosphamide • vincristine • daunorubicin
6ms
Cepharanthine synergistically promotes methylprednisolone pharmacodynamics against human peripheral blood mononuclear cells possibly via regulation of P-glycoprotein/glucocorticoid receptor translocation. (PubMed, BMC Complement Med Ther)
CEP synergistically promoted MP pharmacodynamics to decrease the cell viability of the mitogen-activated PBMCs, possibly via inhibiting P-glycoprotein function and potentiating GC receptor translocation. The present study provides new evidence of the therapeutic effect of Cepharanthin® alone or in combination with GC for the management of chronic ITP.
PK/PD data • Journal
|
CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL2RA (Interleukin 2 receptor, alpha) • CD4 (CD4 Molecule) • IL10 (Interleukin 10) • FOXP3 (Forkhead Box P3) • IL17A (Interleukin 17A)
|
ABCB1 expression
|
daunorubicin
6ms
(2,6-Dimethylphenyl)arsonic Acid Induces Apoptosis through the Mitochondrial Pathway, Downregulates XIAP, and Overcomes Multidrug Resistance to Cytostatic Drugs in Leukemia and Lymphoma Cells In Vitro. (PubMed, Int J Mol Sci)
Further experiments showed that As2 overcomes multidrug resistance and sensitizes drug-resistant leukemia and lymphoma cell lines to treatments with the common cytostatic drugs vincristine, daunorubicin, and cytarabine at low micromolar concentrations. Downregulation of XIAP (x-linked inhibitor of apoptosis protein) and apoptosis induction independent of Bcl-2 (B-cell lymphoma 2) and caspase-3 expression levels suggest the activation of additional apoptosis-promoting mechanisms. Due to the selective apoptosis induction, the synergistic effects with common anti-cancer drugs, and the ability to overcome multidrug resistance in vitro, As2 represents a promising candidate for further preclinical investigations with respect to refractory malignancies.
Preclinical • Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • FADD (Fas associated via death domain) • CASP3 (Caspase 3) • CASP9 (Caspase 9) • XIAP (X-Linked Inhibitor Of Apoptosis)
|
cytarabine • vincristine • daunorubicin
6ms
Optimum Induction Therapy of Low-risk APL (clinicaltrials.gov)
P=N/A, N=74, Recruiting, Peking University People's Hospital | Trial primary completion date: Feb 2024 --> Dec 2024
Trial primary completion date
|
RARA (Retinoic Acid Receptor Alpha) • PML (Promyelocytic Leukemia)
|
etoposide IV • daunorubicin
6ms
Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia (clinicaltrials.gov)
P1, N=40, Completed, Wake Forest University Health Sciences | Unknown status --> Completed | Phase classification: P2 --> P1
Trial completion • Phase classification
|
cytarabine • daunorubicin • Starasid (cytarabine ocfosfate)
7ms
Pharmacological p38 MAPK inhibitor SB203580 enhances AML stem cell line KG1a chemosensitivity to daunorubicin by promoting late apoptosis, cell growth arrest in S-phase, and miR-328-3p upregulation. (PubMed, Saudi Pharm J)
Remarkably, the enhanced KG1a cell sensitivity to DNR after SB203580 pretreatment was associated with an increased upregulation of miR-328-3p and slight downregulation of miR-26b-5p, compared to DNR effect. Altogether, these findings could contribute to the development of a new therapeutic strategy by targeting the p38 MAPK pathway to improve treatment outcomes in patients with refractory or relapsed AML.
Preclinical • Journal • IO biomarker
|
TP53 (Tumor protein P53) • BCL2 (B-cell CLL/lymphoma 2) • CASP3 (Caspase 3) • CASP9 (Caspase 9) • CASP7 (Caspase 7) • MIR328 (MicroRNA 328) • CCNB1 (Cyclin B1)
|
BCL2 expression • TP53 expression
|
daunorubicin
7ms
VITAL: Vosaroxin and Infusional Cytarabine in Treating Patients With Untreated Acute Myeloid Leukemia (clinicaltrials.gov)
P2, N=42, Active, not recruiting, Vanderbilt-Ingram Cancer Center | Trial completion date: Apr 2024 --> Sep 2024
Trial completion date • Combination therapy • Tumor mutational burden
|
SRC (SRC Proto-Oncogene)
|
cytarabine • Qinprezo (vosaroxin) • Starasid (cytarabine ocfosfate)
7ms
Vosaroxin and Azacitidine in Treating Patients With Myelodysplastic Syndromes (clinicaltrials.gov)
P1, N=35, Completed, Washington University School of Medicine | Active, not recruiting --> Completed
Trial completion
|
azacitidine • Qinprezo (vosaroxin)
7ms
Marine-Derived Leads as Anticancer Candidates by Disrupting Hypoxic Signaling through Hypoxia-Inducible Factors Inhibition. (PubMed, Mar Drugs)
However, despite the massive increase in the number of marine natural products classified as 'anticancer leads,' most of which correspond to general cytotoxic agents, and only a few have been characterized regarding their molecular targets and mechanisms of action. The current review presents a critical analysis of inhibitors of HIF-1 and HIF-2 and hypoxia-selective compounds that have been sourced from marine organisms and that might act as new chemotherapeutic candidates or serve as templates for the development of structurally similar derivatives with improved anticancer efficacy.
Review • Journal
|
HIF1A (Hypoxia inducible factor 1, alpha subunit)
|
Aplidin (plitidepsin) • echinomycin
7ms
Efficacy and Safety of MTBF Conditioning Regimen for Salvageable Allo-HSCT in the Treatment of R/R AML (clinicaltrials.gov)
P=N/A, N=37, Not yet recruiting, First Affiliated Hospital Xi'an Jiaotong University
New trial
|
fludarabine IV • thiotepa • busulfan • Duoenda (mitoxantrone liposomal)
7ms
Synthesis and biological evaluation of echinomycin analogues as potential colon cancer agent. (PubMed, Sci Rep)
Analogue 3 exhibited superior in vivo efficacy to echinomycin without significant toxicity in mouse xenograft model. The low dose of 3 needed to be efficacious in vivo is also noteworthy and our data suggest that 3 is an attractive and potentially novel agent for the treatment of colon cancer.
Journal
|
HIF1A (Hypoxia inducible factor 1, alpha subunit)
|
echinomycin
8ms
New P3 trial
|
azacitidine • daunorubicin • Duoenda (mitoxantrone liposomal)
8ms
Modulated Electro-Hyperthermia Accelerates Tumor Delivery and Improves Anticancer Activity of Doxorubicin Encapsulated in Lyso-Thermosensitive Liposomes in 4T1-Tumor-Bearing Mice. (PubMed, Int J Mol Sci)
In this study, we investigated whether mEHT accelerates the tumor-specific delivery of doxorubicin (DOX) from lyso-thermosensitive liposomal doxorubicin (LTLD) and improves its anticancer efficacy in mice bearing a triple-negative breast cancer cell line (4T1)...The body weight loss was similar in all mice treated with any DOX formulation, suggesting no difference in toxicity. In conclusion, LTLD combined with mEHT represents a novel approach for DOX delivery into cancer tissue.
Preclinical • Journal
|
CASP3 (Caspase 3)
|
pegylated liposomal doxorubicin • ThermoDox (lyso-thermosensitive liposomal doxorubicin)
8ms
Chemotherapy-initiated cysteine-rich protein 61 decreases acute B-lymphoblastic leukemia chemosensitivity. (PubMed, J Cancer Res Clin Oncol)
DNR induces Cyr61 production in B-ALL cells, and increased Cyr61 levels reduce the chemosensitivity of B-ALL cells. Consequently, targeting Cyr61 or related ATM signaling pathway may present a promising treatment strategy to enhance the chemosensitivity of patients with B-ALL.
Journal
|
BCL2 (B-cell CLL/lymphoma 2) • CCN1 (Cellular Communication Network Factor 1)
|
daunorubicin
8ms
New trial
|
Duoenda (mitoxantrone liposomal)
8ms
Valproate modulates the activity of multidrug resistance efflux pumps, as a chemoresistance factor in gastric cancer cells. (PubMed, Mol Biol Rep)
Valproate can affect drug resistance in gastric cancer via a unique mechanism independent of MDR1 expression.
Journal • IO biomarker
|
PTEN (Phosphatase and tensin homolog) • BCL2 (B-cell CLL/lymphoma 2) • ABCB1 (ATP Binding Cassette Subfamily B Member 1) • CASP3 (Caspase 3) • CDKN1A (Cyclin-dependent kinase inhibitor 1A)
|
ABCB1 overexpression • TP53 expression
|
daunorubicin